The combination of AstraZeneca and Bristol-Myers Squibb's dapagliflozin and metformin, a standard diabetes drug, reduced body weight and the incidence of hypoglycemic events more than glipizide plus metformin during a late-stage study involving Type 2 diabetics. Both drug combinations proved effective in lowering patients' hemoglobin HbA1c level within 52 weeks of treatment.

Full Story:

Related Summaries